Ezetimibe is the first selective cholesterol absorption inhibitor to be licenced in the UK. It interferes both with dietary cholesterol absorption and the enterohepatic circulation of cholesterol synthesized by the liver. As monotherapy it leads to modest reductions in plasma low-density lipoprotein cholesterol levels, but has synergistic effects when used with statins. The place of ezetimibe in clinical practice